Use of HPV testing for cervical screening in vaccinated women—Insights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study
Open Access
- 4 February 2016
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 138 (12) , 2922-2931
Abstract
The management of cervical disease is changing worldwide as a result of HPV vaccination and the increasing use of HPV testing for cervical screening. However, the impact of vaccination on the performance of HPV based screening strategies is unknown. The SHEVa (Scottish HPV Prevalence in Vaccinated women) projects are designed to gain insight into the impact of vaccination on the performance of clinically validated HPV assays. Samples collated from women attending for first cervical smear who had been vaccinated as part of a national “catch‐up” programme were tested with three clinically validated HPV assays (2 DNA and 1 RNA). Overall HR‐HPV and type specific positivity was assessed in total population and according to underlying cytology and compared to a demographically equivalent group of unvaccinated women. HPV prevalence was significantly lower in vaccinated women and was influenced by assay‐type, reducing by 23‐25% for the DNA based assays and 32% for the RNA assay (p = 0.0008). All assays showed over 75% reduction of HPV16 and/or 18 (p < 0.0001) whereas the prevalence of non 16/18 HR‐HPV was not significantly different in vaccinated vs unvaccinated women. In women with low grade abnormalities, the proportion associated with non 16/18 HR‐HPV was significantly higher in vaccinated women (p < 0.0001). Clinically validated HPV assays are affected differentially when applied to vaccinated women, dependent on assay chemistry. The increased proportion of non HPV16/18 infections may have implications for clinical performance, consequently, longitudinal studies linking HPV status to disease outcomes in vaccinated women are warranted.Keywords
Funding Information
- Scottish HPV Archive, a resource for research (www.shine.mvm.ed.ac.uk/archive) setup through Programme Grant from the Chief Scientist Office of the Scottish Government (CZB/4/658)
This publication has 20 references indexed in Scilit:
- Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trialsThe Lancet, 2014
- Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impactBMC Infectious Diseases, 2013
- Vaccine-Type Human Papillomavirus and Evidence of Herd Protection After Vaccine IntroductionPediatrics, 2012
- Aggregation and Competitive Exclusion: Explaining the Coexistence of Human Papillomavirus Types and the Effectiveness of Limited Vaccine Conferred Cross-ImmunityActa Biotheoretica, 2012
- Potential overestimation of HPV vaccine impact due to unmasking of non-vaccine types: Quantification using a multi-type mathematical modelVaccine, 2012
- Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (The FASE Study)Gynecologic Oncology, 2012
- Biased amplification of human papillomavirus DNA in specimens containing multiple human papillomavirus types by PCR with consensus primersCancer Science, 2011
- Evaluation of 14 triage strategies for HPV DNA‐positive women in population‐based cervical screeningInternational Journal of Cancer, 2011
- HPV type-specific prevalence using a urine assay in unvaccinated male and female 11- to 18-year olds in ScotlandBritish Journal of Cancer, 2011
- The Elevated 10-Year Risk of Cervical Precancer and Cancer in Women With Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV Testing in Clinical PracticeJNCI: Journal of the National Cancer Institute, 2005